1 허정은, "그레이브스병 환자에게서 유전자재조합 사람 TSH 수용체를 이용한 2세대 TSH 결합억제 면역글로불린 측정법의 임상적 유용" 대한내분비학회 23 (23): 179-185, 2008
2 권혜미, "Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease" 대한내분비학회 31 (31): 300-310, 2016
3 Stefanic M, "Thyroid peroxidase autoantibodies are associated with a lesser likelihood of late reversion to hyperthyroidism after successful non-ablative treatment of Graves’ disease in Croatian patients" 37 : 71-77, 2014
4 Katahira M, "Thyroglobulin autoantibodies are associated with refractoriness to antithyroid drug treatment for Graves’ disease" 55 : 1519-1524, 2016
5 Takaichi Y, "The significance of antithyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves’ disease treated with antithyroidal drugs" 68 : 1097-1100, 1989
6 Weetman AP, "The immunomodulatory effects of antithyroid drugs" 4 : 145-146, 1994
7 문재훈, "The Diagnosis and Management of Hyperthyroidism in Korea: Consensus Report of the Korean Thyroid Association" 대한내분비학회 28 (28): 275-279, 2013
8 Carella C, "Serum thyrotropin receptor antibodies concentrations in patients with Graves’ disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period" 16 : 295-302, 2006
9 Hamada N, "Retrospective reevaluation of the significance of thyroid microsomal antibody in the treatment of Graves’ disease" 114 : 328-335, 1987
10 Laurberg P, "Remission of Graves’ disease during anti-thyroid drug therapy. Time to reconsider the mechanism?" 155 : 783-786, 2006
1 허정은, "그레이브스병 환자에게서 유전자재조합 사람 TSH 수용체를 이용한 2세대 TSH 결합억제 면역글로불린 측정법의 임상적 유용" 대한내분비학회 23 (23): 179-185, 2008
2 권혜미, "Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease" 대한내분비학회 31 (31): 300-310, 2016
3 Stefanic M, "Thyroid peroxidase autoantibodies are associated with a lesser likelihood of late reversion to hyperthyroidism after successful non-ablative treatment of Graves’ disease in Croatian patients" 37 : 71-77, 2014
4 Katahira M, "Thyroglobulin autoantibodies are associated with refractoriness to antithyroid drug treatment for Graves’ disease" 55 : 1519-1524, 2016
5 Takaichi Y, "The significance of antithyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves’ disease treated with antithyroidal drugs" 68 : 1097-1100, 1989
6 Weetman AP, "The immunomodulatory effects of antithyroid drugs" 4 : 145-146, 1994
7 문재훈, "The Diagnosis and Management of Hyperthyroidism in Korea: Consensus Report of the Korean Thyroid Association" 대한내분비학회 28 (28): 275-279, 2013
8 Carella C, "Serum thyrotropin receptor antibodies concentrations in patients with Graves’ disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period" 16 : 295-302, 2006
9 Hamada N, "Retrospective reevaluation of the significance of thyroid microsomal antibody in the treatment of Graves’ disease" 114 : 328-335, 1987
10 Laurberg P, "Remission of Graves’ disease during anti-thyroid drug therapy. Time to reconsider the mechanism?" 155 : 783-786, 2006
11 Laurberg P, "Relapse following antithyroid drug therapy for Graves’ hyperthyroidism" 21 : 415-421, 2014
12 Sun Mi Hwang, "Predictive factors for early response to methimazole in children and adolescents with Graves disease: a single-institute study between 1993 and 2013" 대한소아내분비학회 21 (21): 70-74, 2016
13 Smycznyska J, "Persistent remission of Graves’ disease or evolution from Graves’ disease to Hashimoto’s thyroiditis in childhood : a report of 6 cases and clinical implications" 35 : 335-341, 2014
14 Burch HB, "Management of Graves disease : a review" 314 : 2544-2554, 2015
15 Schott M, "Improved prediction of relapse of Graves’ thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies" 39 : 56-61, 2007
16 Smith TJ, "Graves’ disease" 375 : 1552-1565, 2016
17 Wilmar M. Wiersinga, "Graves’ Disease: Can It Be Cured?" 대한내분비학회 34 (34): 29-38, 2019
18 최훈성, "Free Thyroxine, Anti-Thyroid Stimulating Hormone Receptor Antibody Titers, and Absence of Goiter Were Associated with Responsiveness to Methimazole in Patients with New Onset Graves' Disease" 대한내분비학회 32 (32): 281-287, 2017
19 Chiovato L, "Expression of the microsomal antigen on the surface of continuously cultured rat thyroid cells is modulated by thyrotropin" 61 : 12-16, 1985
20 Guilhem I, "Differential evolution of thyroid peroxidase and thyrotropin receptor antibodies in Graves’ disease : thyroid peroxidase antibody activity reverts to pretreatment level after carbimazole withdrawal" 16 : 1041-1045, 2006
21 Romaldini JH, "Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves’ hyperthyroidism" 57 : 563-570, 1983
22 Marcocci C, "Changes of circulating thyroid autoantibody levels during and after the therapy with methimazole in patients with Graves’ disease" 5 : 13-19, 1982
23 Struja T, "Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis" 176 : 87-97, 2017
24 Liu J, "Antithyroid drug therapy for Graves’ disease and implications for recurrence" 2017 : 3813540-, 2017